- Home
- KBDC vs VOR Comparison
KBDC vs VOR Comparison
Compare KBDC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBDC | VOR |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 767.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KBDC | VOR |
|---|---|---|
| Price | $14.92 | $14.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.50 | ★ $45.33 |
| AVG Volume (30 Days) | 264.7K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $8.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $0.13 |
| 52 Week High | $16.40 | $49.95 |
Technical Indicators
Market Signals| Indicator | KBDC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 46.52 |
| Support Level | $14.01 | $11.74 |
| Resistance Level | $15.41 | $14.73 |
| Average True Range (ATR) | 0.32 | 1.03 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 97.14 | 22.01 |
Price Performance
Historical ComparisonAbout KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.